125 related articles for article (PubMed ID: 37598671)
21. Cardiac tamponade after thrombolysis.
Heymann TD; Culling W
Postgrad Med J; 1994 Jun; 70(824):455-6. PubMed ID: 8029170
[TBL] [Abstract][Full Text] [Related]
22. Adverse Event Profile of Azacitidine: Analysis by Route of Administration Using Japanese Pharmacovigilance Database.
Yamaoka K; Fujiwara M; Uchida M; Uesawa Y; Muroi N; Shimizu T
Oncology; 2023; 101(10):664-674. PubMed ID: 37279701
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular Safety of Denosumab Across Multiple Indications: A Systematic Review and Meta-Analysis of Randomized Trials.
Seeto AH; Abrahamsen B; Ebeling PR; Rodríguez AJ
J Bone Miner Res; 2021 Jan; 36(1):24-40. PubMed ID: 32780899
[TBL] [Abstract][Full Text] [Related]
24. Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma.
Chen JH; Lenihan DJ; Phillips SE; Harrell SL; Cornell RF
Cardiooncology; 2017; 3():4. PubMed ID: 32154000
[TBL] [Abstract][Full Text] [Related]
25. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
Sato K; Mano T; Iwata A; Toda T
J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
[TBL] [Abstract][Full Text] [Related]
26. Safety Signal between Azacitidine and Pericarditis.
Chu B; Venkatakrishnan A; Aggarwal P
Chemotherapy; 2023; 68(2):115-118. PubMed ID: 35981518
[TBL] [Abstract][Full Text] [Related]
27. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
[TBL] [Abstract][Full Text] [Related]
28. Multivariable predictors of postoperative cardiac adverse events after general and vascular surgery: results from the patient safety in surgery study.
Davenport DL; Ferraris VA; Hosokawa P; Henderson WG; Khuri SF; Mentzer RM
J Am Coll Surg; 2007 Jun; 204(6):1199-210. PubMed ID: 17544078
[TBL] [Abstract][Full Text] [Related]
29. [Ten questions about cardiac tamponade].
Imazio M
G Ital Cardiol (Rome); 2018 Sep; 19(9):471-478. PubMed ID: 30087507
[TBL] [Abstract][Full Text] [Related]
30. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
Shu Y; Chen J; Ding Y; Zhang Q
Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
[TBL] [Abstract][Full Text] [Related]
31. Economics of cardiac adverse events after smallpox vaccination: lessons from the 2003 US Vaccination Program.
Ortega-Sanchez IR; Sniadack MM; Mootrey GT
Clin Infect Dis; 2008 Mar; 46 Suppl 3():S168-78. PubMed ID: 18284356
[TBL] [Abstract][Full Text] [Related]
32. Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system.
Shu Y; Ding Y; Liu L; Zhang Q
CNS Neurosci Ther; 2023 Sep; 29(9):2705-2716. PubMed ID: 37032639
[TBL] [Abstract][Full Text] [Related]
33. Needle in the heart: a rare case of cardiac tamponade caused by a migrated foreign body and mimicking ST segment elevation myocardial infarction.
Pólos M; Domokos D; Şulea CM; Benke K; Csikós G; Nagy A; Skoda R; Szabó A; Merkel E; Hartyánszky I; Szabolcs Z; Merkely B; Becker D
BMC Cardiovasc Disord; 2021 Mar; 21(1):143. PubMed ID: 33730997
[TBL] [Abstract][Full Text] [Related]
34. New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database.
Sessa M; Andersen M
BioDrugs; 2021 Mar; 35(2):215-227. PubMed ID: 33609278
[TBL] [Abstract][Full Text] [Related]
35. Churg-Strauss syndrome revealed by granulomatous acute pericarditis: two case reports and a review of the literature.
Agard C; Rendu E; Leguern V; Ponge T; Masseau A; Barrier JH; Trochu JN; Hamidou MA; Guillevin L
Semin Arthritis Rheum; 2007 Jun; 36(6):386-91. PubMed ID: 17303217
[TBL] [Abstract][Full Text] [Related]
36. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.
Suh KJ; Lee JY; Shin DY; Koh Y; Bang SM; Yoon SS; Park S; Kim I; Lee JO
Int J Hematol; 2017 Aug; 106(2):229-239. PubMed ID: 28378056
[TBL] [Abstract][Full Text] [Related]
37. Prediction of drug-related cardiac adverse effects in humans--A: creation of a database of effects and identification of factors affecting their occurrence.
Matthews EJ; Frid AA
Regul Toxicol Pharmacol; 2010 Apr; 56(3):247-75. PubMed ID: 19932726
[TBL] [Abstract][Full Text] [Related]
38. Pattern of adverse events induced by aflibercept and ranibizumab: A nationwide spontaneous adverse event reporting database, 2007-2016.
Ha D; Choi SR; Kwon Y; Park HH; Shin JY
Medicine (Baltimore); 2019 Aug; 98(33):e16785. PubMed ID: 31415382
[TBL] [Abstract][Full Text] [Related]
39. The role of infarction-associated pericarditis on the occurrence of atrial fibrillation.
Nagahama Y; Sugiura T; Takehana K; Hatada K; Inada M; Iwasaka T
Eur Heart J; 1998 Feb; 19(2):287-92. PubMed ID: 9519323
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
Ishikawa J; Matsumura I; Kawaguchi T; Kuroda J; Nakamae H; Miyamoto T; Matsuoka KI; Shibayama H; Hino M; Hirase C; Kamimura T; Shimose T; Akashi K; Kanakura Y
Int J Hematol; 2018 May; 107(5):535-540. PubMed ID: 29362980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
